Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722604 · ClinicalTrials.gov registry record · Phase 3
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 258
- Enrollment target
NCT01722604 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 258 participants.
The verdict
NCT01722604, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 258 participants
- Enrollment target
Study Summary
The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.
Interventions
- DRUG brinzolamide 1% ophthalmic suspension
- DRUG Azopt 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01722604
The ClinicalTrials.gov registry entry for NCT01722604 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which brinzolamide 1% ophthalmic suspension is the first listed.
NCT01722604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01722604 about?
NCT01722604 is a clinical study titled "Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt". The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.
What is the current status of trial NCT01722604?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2012-01. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01722604?
The interventions under investigation include: brinzolamide 1% ophthalmic suspension (DRUG), Azopt 1% (DRUG).
Who is sponsoring clinical trial NCT01722604?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.